EP3322823A4 - Verfahren zur diagnose, prognose und überwachung von brustkrebs und reagenzien dafür - Google Patents

Verfahren zur diagnose, prognose und überwachung von brustkrebs und reagenzien dafür Download PDF

Info

Publication number
EP3322823A4
EP3322823A4 EP16823558.8A EP16823558A EP3322823A4 EP 3322823 A4 EP3322823 A4 EP 3322823A4 EP 16823558 A EP16823558 A EP 16823558A EP 3322823 A4 EP3322823 A4 EP 3322823A4
Authority
EP
European Patent Office
Prior art keywords
prognosis
diagnosis
monitoring
methods
breast cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16823558.8A
Other languages
English (en)
French (fr)
Other versions
EP3322823A1 (de
Inventor
Andrew Stone
Elena ZOTENKO
Susan Clark
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Garvan Institute of Medical Research
Original Assignee
Garvan Institute of Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Garvan Institute of Medical Research filed Critical Garvan Institute of Medical Research
Publication of EP3322823A1 publication Critical patent/EP3322823A1/de
Publication of EP3322823A4 publication Critical patent/EP3322823A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP16823558.8A 2015-07-14 2016-07-14 Verfahren zur diagnose, prognose und überwachung von brustkrebs und reagenzien dafür Withdrawn EP3322823A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562192540P 2015-07-14 2015-07-14
PCT/AU2016/050615 WO2017008117A1 (en) 2015-07-14 2016-07-14 Methods for diagnosis, prognosis and monitoring of breast cancer and reagents therefor

Publications (2)

Publication Number Publication Date
EP3322823A1 EP3322823A1 (de) 2018-05-23
EP3322823A4 true EP3322823A4 (de) 2019-06-19

Family

ID=57756617

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16823558.8A Withdrawn EP3322823A4 (de) 2015-07-14 2016-07-14 Verfahren zur diagnose, prognose und überwachung von brustkrebs und reagenzien dafür

Country Status (4)

Country Link
EP (1) EP3322823A4 (de)
CN (1) CN107922977A (de)
AU (1) AU2016293381A1 (de)
WO (1) WO2017008117A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108676879A (zh) * 2018-05-24 2018-10-19 中国科学院北京基因组研究所 特异甲基化位点作为乳腺癌分子分型诊断标志物的应用
US20210230662A1 (en) * 2018-10-14 2021-07-29 Lantern Pharma Inc. Methods for the Treatment of Solid Tumor Cancers Using Illudins and Biomarkers
WO2020252721A1 (en) * 2019-06-20 2020-12-24 The Johns Hopkins University Dna methylation markers and their use in differentiation of suspected cancerous lymph node biopsy samples
WO2021174262A1 (en) * 2020-02-28 2021-09-02 Loma Linda University Methods of evaluating breast cancer prognosis and treatment regimens based on methylation status of the ins-igf2 region
CN111349695A (zh) * 2020-03-30 2020-06-30 陕西科技大学 基于焦磷酸测序技术的gata3基因甲基化检测试剂盒及检测方法
CN111235241A (zh) * 2020-03-30 2020-06-05 陕西科技大学 基于焦磷酸测序技术的foxa1基因甲基化检测试剂盒及检测方法
US20240279740A1 (en) * 2020-07-02 2024-08-22 The Johns Hopkins University Methylated markers for accurate detection of primary central nervous system and systemic diffuse large b cell lymphoma
WO2022123419A1 (en) * 2020-12-08 2022-06-16 Pfizer Inc. Treatment of luminal subtypes of hr-positive, her2-negative early breast cancer with palbociclib
CN114480652A (zh) * 2022-02-21 2022-05-13 深圳市陆为生物技术有限公司 评价乳腺癌患者对于辅助内分泌治疗的响应性的产品

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003000189A2 (en) * 2001-06-21 2003-01-03 Baylor College Of Medicine Prediction, diagnosis and treatment of endocrine resistant breast cancer, using p38 mapk pathway
WO2006004597A2 (en) * 2004-06-01 2006-01-12 University Of Southern California Association of breast cancer dna methylation profiles with hormone receptor status and response to tamoxifen

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2665834A1 (de) * 2011-01-20 2013-11-27 Université Libre de Bruxelles Epigene portraits von menschlichem brustkrebs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003000189A2 (en) * 2001-06-21 2003-01-03 Baylor College Of Medicine Prediction, diagnosis and treatment of endocrine resistant breast cancer, using p38 mapk pathway
WO2006004597A2 (en) * 2004-06-01 2006-01-12 University Of Southern California Association of breast cancer dna methylation profiles with hormone receptor status and response to tamoxifen

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CAROLYN L SMITH ET AL: "Elevated nuclear expression of the SMRT corepressor in breast cancer is associated with earlier tumor recurrence", BREAST CANCER RESEARCH AND TREATMENT, KLUWER ACADEMIC PUBLISHERS, BO, vol. 136, no. 1, 27 September 2012 (2012-09-27), pages 253 - 265, XP035125727, ISSN: 1573-7217, DOI: 10.1007/S10549-012-2262-7 *
K W MERRELL ET AL: "Differential recruitment of nuclear receptor coregulators in ligand-dependent transcriptional repression by estrogen receptor-[alpha]", ONCOGENE, vol. 30, no. 13, 22 November 2010 (2010-11-22), London, pages 1608 - 1614, XP055587477, ISSN: 0950-9232, DOI: 10.1038/onc.2010.528 *
L. ZHANG ET AL: "SpliceArray Profiling of Breast Cancer Reveals a Novel Variant of NCOR2/SMRT That Is Associated with Tamoxifen Resistance and Control of ER? Transcriptional Activity", CANCER RESEARCH, vol. 73, no. 1, 1 November 2012 (2012-11-01), Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA, pages 246 - 255, XP055367636, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-12-2241 *
RYO AKIHIDE ET AL: "Pinning down HER2-ER crosstalk in SMRT regulation.", TRENDS IN BIOCHEMICAL SCIENCES APR 2009, vol. 34, no. 4, April 2009 (2009-04-01), pages 162 - 165, XP002791216, ISSN: 0968-0004 *
See also references of WO2017008117A1 *
T VAN AGTHOVEN ET AL: "CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer", BRITISH JOURNAL OF CANCER, vol. 101, no. 11, 10 November 2009 (2009-11-10), GB, pages 1824 - 1832, XP055587459, ISSN: 0007-0920, DOI: 10.1038/sj.bjc.6605423 *

Also Published As

Publication number Publication date
CN107922977A (zh) 2018-04-17
EP3322823A1 (de) 2018-05-23
AU2016293381A1 (en) 2018-01-25
WO2017008117A1 (en) 2017-01-19

Similar Documents

Publication Publication Date Title
AU2015318823A1 (en) Methods for diagnosis, prognosis and monitoring of breast cancer and reagents therefor
EP3524689A4 (de) Verfahren zur prognose von brustkrebspatienten
EP3322823A4 (de) Verfahren zur diagnose, prognose und überwachung von brustkrebs und reagenzien dafür
EP3425055A4 (de) Reagens für molekulardetektion/-diagnostik von tumoren
EP3156498A4 (de) Brustkrebsnachweiskit oder -vorrichtung und verfahren zum nachweis von brustkrebs
EP3177739A4 (de) Mikro-rna-biomarker zur diagnose von magenkrebs
EP3359692A4 (de) Verfahren zur klassifizierung und behandlung von krebs
HK1208501A1 (en) Method for the diagnosis, prognosis and treatment of lung cancer metastasis
EP3126814A4 (de) Verfahren und system zur diagnose und prognose von krebs
EP3622071A4 (de) Zirkulierende rna zur detektion, vorhersage und überwachung von krebs
EP3180450A4 (de) Verfahren zur prognose von ovarialkarzinom und patientenstratifizierung
EP2988131A4 (de) Genetischer marker für frühe brustkrebsprognose und diagnose sowie verwendung
EP3230745A4 (de) Plasma-autoantikörperbiomarker für basalen brustkrebs
EP2996721A4 (de) Verfahren und zusammensetzungen zur prognose, diagnose und behandlung von adam8-exprimierendem krebs
EP3298145A4 (de) Verfahren zur diagnose von brustkrebs
EP3149210A4 (de) Verfahren und system für lungenkrebsdiagnose
EP4202441A3 (de) Genexpressionsprofil in makrophagen zur diagnose von krebs
EP3430406B8 (de) Verfahren zur krebsdiagnose und -prognose
MA40636A (fr) Procédés pour détecter le cancer de la prostate
EP3134545A4 (de) Verfahren und biomarker zum nachweis von krebs
EP3292218A4 (de) Zusammensetzungen und verfahren zur überwachung, diagnose, prognose, detektion und behandlung von krebs
EP3415914A4 (de) Verfahren, biomarker und diagnostikum zur detektion von hochrisiko-prostatakrebs
GB201619808D0 (en) Biomarkers for the prognosis and diagnosis of cancer
EP3639028A4 (de) Diagnostische, prognostische und überwachungsverfahren für maligne solide tumoren
EP3702784A4 (de) Verfahren zur diagnose von krebs aus blut

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180205

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20190522

RIC1 Information provided on ipc code assigned before grant

Ipc: C12Q 1/48 20060101ALI20190514BHEP

Ipc: C12Q 1/68 20180101AFI20190514BHEP

Ipc: G01N 33/574 20060101ALI20190514BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20191218